Do CYP2D6 polymorphisms affect the efficacy and toxicity of flecainide? A cohort study
Sign Up to like & getrecommendations! Published in 2024 at "European Heart Journal"
DOI: 10.1093/eurheartj/ehae666.522
Abstract: The CYP2D6 enzyme, coded by the CYP2D6 gene, is the primary metabolic pathway for flecainide.(1,2) Over the years, studies on how different variants of this gene affect flecainide metabolism and efficacy have yielded contradictory results.(3–7)… read more here.
Keywords: toxicity flecainide; efficacy toxicity; toxicity; cohort study ... See more keywords